Pathology has remained largely static for over a century: tissue fixed on glass, glass mounted on a microscope stage, and a pathologist confined to a physical office. Digital pathology disrupts these three constraints, ushering in a paradigm shift toward data-driven diagnostics.
This guide provides a comprehensive technical overview: defining the modality, optimizing the diagnostic workflow, evaluating capital expenditures, and projecting the trajectory of computational integration.
In this guide
- What Is Digital Pathology?
- Why Digital Pathology Matters
- Digital Pathology Workflow: From Biopsy to Sign-Out
- Why the Workflow Should Start Before the Scanner
- Digital Pathology vs. Traditional Light Microscopy
- Benefits of Digital Pathology
- Regulatory Status and FDA Clearance
- Evaluating Digital Pathology Systems
- Challenges to Implementation
- Key Applications
- The Future: Computational Pathology
- Frequently Asked Questions
What Is Digital Pathology?
Digital pathology is the practice of digitizing specimen data to facilitate the acquisition, management, and interpretation of pathology information in a computer-mediated environment. Rather than utilizing a traditional light microscope for primary diagnosis, glass slides are processed via high-throughput scanners to generate Whole Slide Images (WSI). These ultra-high-resolution, multi-gigapixel files are then rendered on high-definition medical-grade displays for remote or local sign-out.
A robust digital pathology system comprises four critical pillars:
- Whole Slide Imaging (WSI) Scanners: Optomechanical devices that digitize glass slides into high-fidelity image files.
- Digital Pathology Software (Viewer): A sophisticated interface allowing pathologists to navigate, pan, and annotate virtual slides at varying magnifications.
- Image Management System (IMS): A secure repository for the storage, retrieval, and algorithmic routing of digital cases.
- Bidirectional Laboratory Information System (LIS) Integration: A seamless handshake with the LIS to synchronize patient metadata and diagnostic reporting.
By replacing the traditional microscope as the primary diagnostic interface, these systems introduce computational capabilities that exceed the limitations of analog optics.
Why Digital Pathology Matters
Digital pathology matters because it removes the physical limits on who can review a case, where, and how fast. When slides are digital, a case can reach the right subspecialist the same day instead of after an overnight shipment, a second opinion takes minutes rather than days, and every prior case is searchable from the pathologist’s desk. For patients, that means faster answers; for labs, fewer couriers, less slide storage and more capacity without adding staff; and for pathologists, the ability to work across sites and use AI tools that a microscope can’t run.
The diagnostic skill of an experienced pathologist reading a well-prepared glass slide isn’t in question. The case for going digital is that the logistics around glass slides limit what pathologists can do, where they can do it, and who they can work with. For an honest look at whether that trade is worth it for a specific practice, see Is Digital Pathology Worth It? A Guide for Pathologists Who Aren’t Convinced Yet.
Digital Pathology Workflow: From Biopsy to Sign-Out
Modern digital pathology transcends simple image capture; it optimizes the entire specimen lifecycle.
1. Specimen Procurement and Tissue Handling
The process begins with the acquisition of a core biopsy, surgical resection, or cytology specimen. Traditional workflows often suffer from tissue fragmentation or loss of orientation during transport. Advanced digital systems, such as Lumea’s, utilize specialized tissue-handling devices to maintain spatial orientation and specimen integrity at the point of extraction.
In practice, this means rethinking the containers biopsies travel in. With a traditional prostate biopsy, each of 12 cores goes into its own jar with its own label. With Lumea’s BxBoard, cores are laid in site-specific lanes on formalin-soaked sponges, so a 12-core biopsy fits on two six-lane boards. The cores stay flat and oriented, the procedure room handles fewer containers and labels, and staff have less exposure to formaldehyde. Because the location of every core is recorded at collection, the pathologist can later localize and quantify disease by site without reconstructing it from jar labels.
2. Histologic Processing
Grossing and embedding are where small biopsies are most often lost, fragmented or misoriented. Two tools change that step. A smart grossing camera like the BxCamera uses machine
learning to count and measure each tissue fragment and can populate the gross description directly into the LIS. A tissue array like the BxChip holds multiple cores in a single plane through
processing, embedding and microtomy, so six prostate cores can be embedded together in seconds, with fewer blocks and slides per case. Because the tissue arrives on the slide in a known layout, the viewer can track which core is which during sign-out.
3. High-Throughput Digitization (Scanning)
Glass slides are loaded into a WSI scanner. The system captures the entire tissue area at high numerical aperture (typically equivalent to 20x or 40x magnification). The resulting WSI provides a continuous focal plane, allowing for rapid digital “zooming” without the mechanical latency of changing objectives.
4. Virtual Interpretation and Diagnosis
The WSI is routed to a specialized viewer. Pathologists can navigate the specimen, utilize digital measurement tools, and apply annotations to Regions of Interest (ROI). This environment facilitates ergonomic sign-out from any location with secure, high-speed network access.
5. Computational Pathology and AI Augmentation
Third-party AI algorithms can be deployed directly into the workflow. These tools perform quantitative analysis—such as mitotic figure counting, biomarker quantification (e.g., Ki-67, HER2), and automated screening for micrometastases. AI serves as a “first-look” or concurrent assist, reducing cognitive load and intra-observer variability.
6. Synoptic Reporting and LIS Synchronization
The final diagnosis is integrated into a synoptic report and transmitted back to the LIS. The digital nature of the workflow ensures a robust audit trail and significantly reduces the turnaround time (TAT) by eliminating physical slide distribution.
Why the Workflow Should Start Before the Scanner
Most digital pathology systems begin when a lab scans a slide. Added that way, digital becomes an extra step: the lab still does all of its manual handling, then pays to scan on top of it. That is a big part of why early adopters found that going digital added cost and time instead of saving it. The labs that get a return from digital pathology tend to rethink the whole chain, starting at the point of tissue acquisition. Standardizing how tissue is collected, oriented and embedded means fewer manual steps in the lab, better-quality slides for the scanner, and more usable tissue for the pathologist. In published research on Lumea’s prostate workflow, standardized tissue handling was associated with an 18.79% higher cancer detection rate.
It also changes how practices can adopt. Because the improvements start before the scanner, a lab can begin with tissue handling or the viewer alone and add the rest later, rather than committing to a full platform on day one.
Digital Pathology vs. Traditional Light Microscopy
| Feature | Traditional Microscopy | Digital Pathology |
| Diagnostic Interface | Optical eyepieces (fixed location) | High-res monitors (location-agnostic) |
| Consultation | Physical slide shipping (24–72 hours) | Instant link/portal access (seconds) |
| Image Analysis | Manual/Qualitative estimation | Algorithmic/Quantitative precision |
| Archiving | Physical slide libraries (degrades/breaks) | Redundant digital storage (lossless) |
| Ergonomics | Static posture (neck/back strain) | Dynamic, ergonomic workstation |
| Case Integration | Manual cross-referencing of files | Side-by-side digital comparison |
The honest answer is that traditional microscopy isn’t going away; glass slides will be part of pathology workflows for years. But digital pathology removes the bottlenecks that have held back efficiency, collaboration, and the adoption of AI-powered tools.
Technical and Clinical Benefits of Digital Pathology
For Pathologists
Remote work is the most immediate benefit: pathologists are no longer tied to a single location or institution. A subspecialty expert in Boston can consult on a case in rural Utah without shipping slides. But beyond location flexibility, digital pathology changes the nature of diagnostic work:
- Side-by-side viewing of multiple slides simultaneously, impossible with a single microscope
- Instant access to prior cases for comparison
- Annotation tools that create a documented, shareable diagnostic record
- Better ergonomics, no hunching over an eyepiece for hours
- AI augmentation for high-volume, repetitive analysis tasks
- Remote sign-out with work-from-home capabilities and multi-site coverage
- Enhanced precision with access to digital measurement tools and side-by-side comparison of different stains (e.g., H&E and IHC) on the same screen
- Eliminates the “glass sorting” and manual retrieval of historical slides
For Labs
- Reduction in courier costs and physical storage footprints
- Automated identification of tissue artifacts or out-of-focus scans prior to pathologist review
- Allows the lab to increase volume without a linear increase in physical administrative staff
- A permanent, searchable digital archive that doesn’t degrade over time
For the Patient
- Faster diagnostic intervals lead to expedited treatment planning
- Enables rapid “tele-consults” with world-renowned experts, regardless of geography
Weighing digital pathology for your group? See what changes for your lab’s workflow, staffing and turnaround. Request a demo from us today.
Regulatory Status and FDA Clearance
The FDA regulates digital pathology systems used for primary diagnosis as medical devices. The first whole slide imaging system was authorized for primary diagnosis through the de novo pathway in 2017, and other systems have since followed through 510(k) clearance. During the COVID-19 public health emergency, a temporary 2020 FDA enforcement policy relaxed requirements so pathologists could review slides remotely; that policy has ended, so the scope of each system’s clearance matters again. Lumea’s Viewer+ received FDA 510(k) clearance in March 2025 and is CE marked under the EU In Vitro Diagnostic Regulation (IVDR). Whichever system a lab chooses, it still validates the system in its own setting, following College of American Pathologists (CAP) guidelines, before clinical use.
FDA Premarket Notification Database: 510(k) Number K242244 for Viewer+
Evaluating Digital Pathology Systems (DPS)
When selecting a DPS, stakeholders must prioritize:
- Rendering performance: The ability to stream multi-gigabyte images without latency (tiling/stuttering) is paramount for user adoption.
- Interoperability: The system must be scanner-agnostic and offer deep integration with EHRs and LIS (e.g., Epic Beaker, Sunquest).
- Open AI ecosystem: Ensure the software allows for the integration of diverse, third-party computational tools rather than a closed, proprietary “walled garden.”
- Access control and audit trails: Pathology is regulated. Your software needs role-based access, a complete audit log, and compliance with CAP/CLIA requirements.
- Modularity and pre-analytic support: Look for a system you can adopt in stages, and ask what it does before the scanner. Platforms that standardize tissue handling and grossing improve the slides you digitize, not just the way you view them.
Lumea’s platform was designed around these exact requirements: a web-based viewer with LIS integration, an open AI ecosystem, and full access from any device.
Challenges to Implementation
- Capital expenditure (CAPEX): Initial investment in scanners and IT infrastructure (high-speed networking and petabyte-scale storage).
- Validation requirements: Labs must perform internal validation studies (per CAP guidelines) to ensure diagnostic concordance between digital and glass slides.
- Data management: Managing the high data throughput of WSI requires a robust strategy for “hot” and “cold” storage.
- Temporary workflow disruption: Any change to an established lab workflow creates friction. Staff training and change management matter as much as the technology itself.
- Lack of standardization: scanners, file formats and software still vary, which is why scanner-agnostic, standards-based platforms matter.
- A real learning curve: most pathologists see slower throughput for the first few weeks, then recover it once the new workflow becomes habit.
- Rendering speed: lag is one of the most common reasons pathologists abandon a platform, so test it with your own cases before you buy.
- Downtime planning: a sound implementation includes backup scanners, documented downtime procedures and a way to keep cases moving when a component is unavailable.
None of these are dealbreakers; they’re planning requirements. Labs that have implemented digital pathology successfully invest as much in workflow design as they do in the technology.
What Is Digital Pathology Used For? Key Applications
Primary diagnosis: The core use case, where pathologists diagnose surgical pathology cases from digital images instead of glass slides.
Teleconsultation and second opinions: Sending cases to subspecialty experts or academic centers without shipping physical slides.
Tumor boards: Displaying cases on a shared screen during multidisciplinary tumor board meetings, with full zoom and annotation capability.
Medical education: Teaching pathology with a digital library of cases rather than glass slide collections.
Research and clinical trials: Digital images can be analyzed at scale with AI, enabling biomarker discovery and quantitative research that isn’t possible with manual microscopy.
AI development and deployment: Every major AI pathology company builds and validates models on digital pathology images.
The Future: Computational Pathology
Computer analysis of pathology images dates back to the 1960s; what has changed is that whole slide imaging now produces the data at clinical scale. The industry is moving toward Computational Pathology, where the WSI is not just a picture, but a data set. Future developments include:
- Predictive Analytics: AI that predicts molecular signatures or treatment responses directly from H&E morphology.
- Integrated Spatial Biology: Combining WSI with spatial transcriptomics for a “multi-omic” view of the tumor microenvironment.
- Decentralized Expert Networks: A globalized marketplace for subspecialty expertise, removing the “silo” effect of physical hospitals.
Lumea remains at the forefront of this evolution, providing the integrated infrastructure necessary for a fully digital, AI-ready diagnostic environment.
Frequently Asked Questions
What is the difference between digital pathology and computational pathology?
Digital pathology refers to the broader practice of digitizing and managing pathology images. Computational pathology specifically refers to the use of algorithms and AI to analyze those images. All computational pathology requires digital pathology, but not all digital pathology uses computational analysis.
Does digital pathology replace the pathologist?
No. It changes how and where pathologists work, not whether they’re needed. AI tools assist with specific tasks, like counting cells and flagging regions, but the interpretive diagnosis remains the pathologist’s domain.
How long does it take to implement a digital pathology system?
Implementation timelines vary by lab size and complexity. A typical deployment, including scanner installation, software integration, LIS connection, and validation following CAP guidelines, runs three to nine months. Lumea is designed to reduce implementation complexity, particularly around LIS integration and remote access setup.
What scanners work with digital pathology software?
Most modern digital pathology platforms, including Lumea, support images in standard WSI formats (SVS, NDPI, MRXS, etc.) from major scanner manufacturers including Leica, Hamamatsu, Philips, and 3DHistech. Lumea is scanner-agnostic.
Is digital pathology reimbursable?
Reimbursement for these services is evolving. CMS has issued guidance on billing for remote pathology services, and many private payers have followed. Your billing team should review current CPT codes and payer policies specific to your service mix.
Is digital pathology FDA approved?
The FDA authorizes specific digital pathology systems rather than digital pathology as a whole. Whole slide imaging systems have been authorized for primary diagnosis since 2017, and Lumea’s Viewer+ received 510(k) clearance in March 2025. Labs still validate any system in their own setting before clinical use.
Is digital pathology as accurate as a microscope?
Systems cleared for primary diagnosis have shown diagnostic performance comparable to glass slides in clinical studies. Image quality also depends on what happens before scanning: well-oriented, unfragmented tissue makes a better digital slide. See How Digital Pathology Improves Diagnostic Accuracy.
What are the disadvantages of digital pathology?
The main ones are upfront cost, a short learning curve, the need for validation, and storage for very large image files. See Challenges to Implementation above for how labs plan around each.
Is digital pathology worth it for my practice?
It depends on your case volume, number of sites, remote coverage needs and where your workflow slows down. A multi-site group struggling with slide logistics usually sees a faster return than a single-site practice. For a candid walk-through, see Is Digital Pathology Worth It?
Ready to see digital pathology in action? Request a demo of Lumea’s platform by filling out the form below.
